Trials / Conditions / Malignant Melanoma Stage IV

Malignant Melanoma Stage IV

15 registered clinical trials studyying Malignant Melanoma Stage IV — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma NCT06708455	Rapa Therapeutics LLC	Phase 2
Recruiting	[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer NCT07215182	Barbara Malene Fischer	Phase 2
Completed	Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma NCT05304546	Dr. Ronnie Shapira	Phase 2
Terminated	The IRMI-FMT Trial NCT04577729	Medical University of Graz	N/A
Terminated	Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases NCT03430947	Technische Universität Dresden	Phase 2
Completed	Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic NCT03493230	Centre Hospitalier Universitaire de Nice	N/A
Recruiting	Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma NCT03166397	Sheba Medical Center	Phase 2
Completed	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain NCT02439411	Grupo Español Multidisciplinar de Melanoma	—
Unknown	Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI NCT03132090	University Hospital Tuebingen	N/A
Completed	Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemuraf NCT01983124	Paola Queirolo	Phase 2
Completed	mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma NCT01676779	Universitair Ziekenhuis Brussel	Phase 2
Completed	Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Un NCT01302496	Bart Neyns	Phase 2
Completed	IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma NCT01189383	Baylor Research Institute	Phase 1 / Phase 2
Terminated	Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patien NCT00722098	Baylor Research Institute	Phase 2
Completed	Combined Modality Treatment for Patients With Stage IV Melanoma NCT00313235	Baylor Research Institute	Phase 1 / Phase 2